Fda Approves Semaglutide for Cardiovascular Risk Reduction

Fda Approves Semaglutide for Cardiovascular Risk Reduction

The US Food and Drug Administration (Fda) has accredited the anti-being overweight drug semaglutide 2.four mg injection (Wegovy) for cutting down cardiovascular chance in grownups with chubby or weight problems and set up cardiovascular disorder.  The label expansion now incorporates use of the when-weekly glucagon-like peptide one (GLP-1) agonist for minimizing risks for important adverse cardiovascular activities (MACEs) together with …
Read More

You May Also Like